Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 199

1.

Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.

Thompson LL, Jeusset LM, Lepage CC, McManus KJ.

Cancers (Basel). 2017 Nov 1;9(11). pii: E151. doi: 10.3390/cancers9110151. Review.

2.

Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population.

Lopez A, Bouvier AM, Jooste V, Cottet V, Romain G, Faivre J, Manfredi S, Lepage C.

Gut. 2017 Oct 26. pii: gutjnl-2016-312093. doi: 10.1136/gutjnl-2016-312093. [Epub ahead of print]

PMID:
29074726
3.

Age at First Exposure to Repetitive Head Impacts Is Associated with Smaller Thalamic Volumes in Former Professional American Football Players.

Schultz V, Stern RA, Tripodis Y, Stamm J, Wrobel P, Lepage C, Weir I, Guenette JP, Chua A, Alosco ML, Baugh CM, Fritts NG, Martin BM, Chaisson CE, Coleman MJ, Lin AP, Pasternak O, Shenton ME, Koerte IK.

J Neurotrauma. 2017 Nov 17. doi: 10.1089/neu.2017.5145. [Epub ahead of print]

PMID:
28990457
4.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.

PMID:
28922790
5.

[Benefits of volumetric to facial rejuvenation. Part 2: Dermal fillers].

Bui P, Pons Guiraud A, Lepage C.

Ann Chir Plast Esthet. 2017 Oct;62(5):550-559. doi: 10.1016/j.anplas.2017.07.005. Epub 2017 Sep 12. French.

PMID:
28911889
6.

[Benefits of volumetric to facial rejuvenation. Part 1: Fat grafting].

Bui P, Lepage C.

Ann Chir Plast Esthet. 2017 Oct;62(5):532-549. doi: 10.1016/j.anplas.2017.07.004. Epub 2017 Sep 5. French.

PMID:
28886872
7.

White matter abnormalities in mild traumatic brain injury with and without post-traumatic stress disorder: a subject-specific diffusion tensor imaging study.

Lepage C, de Pierrefeu A, Koerte IK, Coleman MJ, Pasternak O, Grant G, Marx CE, Morey RA, Flashman LA, George MS, McAllister TW, Andaluz N, Shutter L, Coimbra R, Zafonte RD, Stein MB, Shenton ME, Bouix S.

Brain Imaging Behav. 2017 Jul 5. doi: 10.1007/s11682-017-9744-5. [Epub ahead of print]

PMID:
28676987
8.

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G.

Endocrine. 2017 Sep;57(3):504-511. doi: 10.1007/s12020-017-1355-9. Epub 2017 Jun 29.

PMID:
28664309
9.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
10.

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

Kientz C, Joly MO, Faivre L, Clemenson A, Dalac S, Lepage C, Chapusot C, Jacquot C, Schiappa R, Lebrun M.

Hered Cancer Clin Pract. 2017 May 12;15:6. doi: 10.1186/s13053-017-0066-9. eCollection 2017.

11.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators.

Eur J Cancer. 2017 Jul;79:158-165. doi: 10.1016/j.ejca.2017.04.009. Epub 2017 May 11.

PMID:
28501762
12.

Impaired Cognitive Performance in Youth Athletes Exposed to Repetitive Head Impacts.

Koerte IK, Nichols E, Tripodis Y, Schultz V, Lehner S, Igbinoba R, Chuang AZ, Mayinger M, Klier EM, Muehlmann M, Kaufmann D, Lepage C, Heinen F, Schulte-Körne G, Zafonte R, Shenton ME, Sereno AB.

J Neurotrauma. 2017 Aug 15;34(16):2389-2395. doi: 10.1089/neu.2016.4960. Epub 2017 Jun 9.

PMID:
28381107
13.

Waldmann's disease: a rare cause of protein losing enteropathy in an adult patient.

Martins CR, Gagnaire A, Rostain F, Lepage C.

Rev Esp Enferm Dig. 2017 May;109(5):385-388. doi: 10.17235/reed.2017.4593/2016.

14.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.

Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.

PMID:
28292641
15.

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P; PETACC8 Investigators.

Ann Oncol. 2017 Apr 1;28(4):824-830. doi: 10.1093/annonc/mdw687.

PMID:
28031175
16.

Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.

Sefrioui D, Vermeulin T, Blanchard F, Chapusot C, Beaussire L, Armengol-Debeir L, Sesboué R, Gangloff A, Hebbar M, Copin MC, Houivet E, Schwarz L, Clatot F, Tuech JJ, Bénichou J, Martin L, Bouvier AM, Sabourin JC, Sarafan-Vasseur N, Frébourg T, Lepage C, Michel P, Di Fiore F.

Int J Cancer. 2017 Apr 1;140(7):1653-1661. doi: 10.1002/ijc.30584.

PMID:
28006840
17.

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study.

Lepage C, Bossard N, Dejardin O, Carmona-Garcia MC, Manfredi S, Faivre J; GRELL EUROCARE-5 Working Group.

Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S48-S55. doi: 10.1097/CEJ.0000000000000305.

PMID:
28005605
18.

The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition.

McAndrew EN, Lepage CC, McManus KJ.

Oncotarget. 2016 Dec 27;7(52):87417-87430. doi: 10.18632/oncotarget.13654.

19.

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD.

J Pathol Clin Res. 2016 Jul 13;2(4):247-258. eCollection 2016 Oct.

20.

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L.

Oncotarget. 2017 Jan 10;8(2):1957-1971. doi: 10.18632/oncotarget.12699.

Supplemental Content

Loading ...
Support Center